A 28-year-old woman from Jharkhand presents with severe malaria: altered mental status, seizures, and a blood glucose of 42 mg/dL. Thick smear shows >5% parasitaemia with predominantly ring forms. What is the drug of choice for immediate parenteral treatment?

Explanation

## Drug of Choice for Severe Malaria **Key Point:** Intravenous artesunate is the WHO-recommended and current gold-standard first-line drug for severe malaria, including cerebral malaria, severe anaemia, acute kidney injury, and pulmonary oedema. ### Clinical Presentation Analysis This patient has **severe malaria** with: - Cerebral involvement (altered mental status, seizures) - Severe hypoglycaemia (42 mg/dL) - High parasitaemia (>5%) - Predominantly ring forms → consistent with P. falciparum ### Why Intravenous Artesunate? **High-Yield:** IV artesunate has been shown in the SEAQUAMAT trial to reduce mortality by ~35% compared to IV quinine in severe malaria. 1. **Mechanism:** Rapid artemisinin derivative action on all parasite stages 2. **Pharmacokinetics:** Rapid IV absorption, high CNS penetration 3. **Efficacy:** Faster parasite clearance than quinine (median 2 days vs 4.5 days) 4. **Safety:** Lower risk of hypoglycaemia, QT prolongation, and cinchonism compared to quinine 5. **Dosing:** 2.4 mg/kg IV at 0, 24, 48 hours, then daily ### Treatment Algorithm for Severe Malaria ```mermaid flowchart TD A[Severe Malaria Suspected]:::outcome --> B{IV artesunate<br/>available?}:::decision B -->|Yes| C[IV Artesunate 2.4 mg/kg<br/>at 0, 24, 48 hrs, then daily]:::action B -->|No| D[IV Quinine 20 mg/kg<br/>loading, then 10 mg/kg]:::action C --> E[Switch to oral artemisinin-based<br/>combination therapy<br/>when tolerated]:::action D --> E E --> F[Complete 3-day course]:::action F --> G[Recovered from severe features]:::outcome ``` ### Comparison of Parenteral Agents for Severe Malaria | Feature | IV Artesunate | IV Quinine | IM Artemether | |---------|---------------|-----------|---------------| | **First-line status** | WHO gold standard | Alternative if artesunate unavailable | Not recommended (slower onset) | | **Mortality reduction** | 35% vs quinine | Baseline | Similar to artesunate | | **CNS penetration** | Excellent | Good | Moderate | | **Hypoglycaemia risk** | Low | High (insulin release) | Moderate | | **Cinchonism** | None | Common (tinnitus, visual disturbance) | None | | **Onset of action** | Rapid (minutes) | Slower (hours) | Slower | | **Availability in India** | Increasingly available | Widely available | Available | **Clinical Pearl:** Even though IV quinine is widely available in India, IV artesunate is now the preferred choice where available due to superior efficacy and safety profile. The patient's severe hypoglycaemia makes quinine particularly risky (quinine stimulates pancreatic insulin release). ### Post-Acute Phase Management After 3 days of parenteral therapy and clinical improvement: - Switch to oral artemisinin-based combination therapy (ACT): artemether-lumefantrine or artesunate-amodiaquine - Complete a full 3-day course of ACT - Manage complications (cerebral oedema, acute kidney injury, severe anaemia) **Mnemonic:** **SEVERE MALARIA = ARTESUNATE** (Artemisinin derivative, Rapid action, Tested in SEAQUAMAT, Excellent CNS penetration, Reduces mortality, Urgent parenteral route)